医学
德诺苏马布
队列
回顾性队列研究
外科
辅助治疗
佐剂
泌尿科
内科学
化疗
骨质疏松症
作者
Chiao Yee Lim,Xingyu Liu,Fangzhou He,Haijie Liang,Yang Yang,Tao Ji,Rongli Yang,Wei Guo
出处
期刊:The bone & joint journal
[British Editorial Society of Bone and Joint Surgery]
日期:2020-02-01
卷期号:102-B (2): 177-185
被引量:12
标识
DOI:10.1302/0301-620x.102b2.bjj-2019-0813.r1
摘要
Aims To investigate the benefits of denosumab in combination with nerve-sparing surgery for treatment of sacral giant cell tumours (GCTs). Methods This is a retrospective cohort study of patients with GCT who presented between January 2011 and July 2017. Intralesional curettage was performed and patients treated from 2015 to 2017 also received denosumab therapy. The patients were divided into three groups: Cohort 1: control group (n = 36); cohort 2: adjuvant denosumab group (n = 9); and cohort 3: neo- and adjuvant-denosumab group (n = 17). Results There were 68 patients within the study period. Six patients were lost to follow-up. The mean follow-up was 47.7 months (SD 23.2). Preoperative denosumab was found to reduce intraoperative haemorrhage and was associated with shorter operating time for tumour volume > 200 cm 3 . A total of 17 patients (27.4%) developed local recurrence. The locoregional control rate was 77.8% (7/9) and 87.5% (14/16) respectively for cohorts 2 and 3, in comparison to 66.7% (24/36) of the control group. The recurrence-free survival (RFS) rate was significantly higher for adjuvant denosumab group versus those without adjuvant denosumab during the first two years: 100% vs 83.8% at one year and 95.0% vs 70.3% at two years. No significant difference was found for the three-year RFS rate. Conclusion Preoperative denosumab therapy was found to reduce intraoperative haemorrhage and was associated with shorter operating times. Adjuvant denosumab was useful to prevent early recurrence during the first two years after surgery. Cite this article: Bone Joint J 2020;102-B(2):177–185.
科研通智能强力驱动
Strongly Powered by AbleSci AI